RapidCell – IPA2007/HR/16IPO/001-0404503
Beneficiary: Ruđer Bošković Institute, Laboratory for system biomedicine
- Faculty of Food Technology and Biotechnology, University of Zagreb
- SemGen Ltd.
Objectives of the action
Strengthening of the ecosystem of SMEs springing up after dissolution of principal national pharmaceutical company Pliva Inc. Establishing the credibility and feasibility of Knowledge Transfer actions between RBI, Uni Zagreb and those SMEs. Marketable system for rapid clinical identification of pathogenic cells and biohazards – RapidCell. This should result from integration of applicant’s research results, expertise on biotechnological processes of the partner (both from public research sector), bioinformatical expertise and commercialization capabilities of the associate (an SME).
Hospitals and clinics (public and private), Schools of Medicine, Technological Departments of Universities, Researchers in Basic Research Labs at HEI/PROs in the region.
High-added value biotech SMEs, pharmaceutical and food technology companies, patients in need of prompt diagnosis (e.g. clinical infections, epidemical outbreaks), general public.
Rapid procedure, lower price leads to higher proportion of the population to be covered with the RapidCell test, and the test being included into increasing number of industrial processes.
WP 1, Systems Biomedicine Lab, RBI, Zagreb [SBL]: a proof of concept of Derivatization Reagent for preparation of target cells for analysis + streamlined procedures for a system for rapid clinical identification of pathogenic cells and biohazards. During the test phase pathogenic cells will be supplied by an authorized agent, Pimezon Ltd., Zagreb.
WP 2, Biotech Dept. of University of Zagreb [BD]: Design, construction and testing of a prototype of this system.
WP 3, SemGen Ltd., Zagreb: prototype transformation into a product demonstrator, identification of competing technologies and selling points, and a route to the market.
WP4, Knowledge Diffusion: prototype system demonstration to Target groups after the first year. Evaluation by Clinical Hospitals Dubrava and Sestre milosrdnice, Zagreb (agreements signed). Workshops for researchers, diagnostics lab managers at the ends of project yrs. Product demonstrations to potential investors and venture capital managers, RBI and Uni Zagreb innovation support units.
- Hospitals and clinics (public and private) who will incorporate the technology in their diagnostics laboratories. RapidCell evaluation phase in hospitals and clinics could immediately start to generate the benefits for patients, which should not be neglected, besides its effect on the promotion and acquisition of the technology.
- Schools of medicine, biotechnology and biomedicine departments and other higher education institutions (HEI) and public research organizations (PRO) who will use the technology in research & education
- Food & biotechnology industry based on microorganisms that may incorporate the technology into their processes – e.g. beverages, fermented milk production lines are in a need for on-line identification of the microorganisms involved in the process.
- Life-science industry
Financial support for the project provided by The European Union
Project’s implementation period
March 20th 2013 – March 19th 2015